Essilor Stellest Earns TIME's Best Inventions 2026 Nod in Health & Wellness

  • Essilor® Stellest® lenses named one of TIME's Best Inventions of 2026 in Health & Wellness category.
  • Lenses received FDA De Novo market authorization in September 2025 for slowing myopia progression in children.
  • Essilor Stellest backed by clinical trials showing efficacy compared to single vision lenses.
  • Nearly 5 billion people projected to be myopic by 2050, highlighting the growing need for myopia management solutions.

EssilorLuxottica's TIME recognition underscores the strategic importance of myopia management in a market where childhood myopia is rising rapidly. With the FDA's backing and growing global awareness, Stellest lenses position EssilorLuxottica as a leader in evidence-based vision care solutions. The company's ability to sustain this momentum will depend on its execution in scaling production and expanding its partner network.

Market Expansion
How EssilorLuxottica will leverage TIME's recognition to accelerate global adoption of Stellest lenses.
Regulatory Dynamics
Whether the FDA's Breakthrough Device designation will facilitate faster approvals for similar innovations.
Competitive Positioning
The pace at which competitors develop comparable myopia management solutions.